50. 100. 150. 200. 250. D0 D2 D4 D6 D8 D10. OSKM+shCtrl. OSKM+shDdx5 ..... (A) A schematic illustration of the Ddx5 knockout strategy using CRISPR/Cas9 in .... RYBP Regulates Kdm2b Expression but Has no Effect on Expression of the ...
Cell Stem Cell, Volume 20
Supplemental Information
RNA Helicase DDX5 Inhibits Reprogramming to Pluripotency by miRNA-Based Repression of RYBP and its PRC1-Dependent and -Independent Functions Huanhuan Li, Ping Lai, Jinping Jia, Yawei Song, Qing Xia, Kaimeng Huang, Na He, Wangfang Ping, Jiayu Chen, Zhongzhou Yang, Jiao Li, Mingze Yao, Xiaotao Dong, Jicheng Zhao, Chunhui Hou, Miguel A. Esteban, Shaorong Gao, Duanqing Pei, Andrew P. Hutchins, and Hongjie Yao
Figure S1 (Related to Figure 1)
2 1 D0
D3
D6
Ddx5 mRNA
D9 D12
4 3 2 1 0
Ctrl
OSKM
2 1 0
pMXs DDX5
Ctrl
OSKM Ctrl
FSC
Oct4-GFP
GFP
5.92%
pW-TRE-DDX5 Oct4-GFP
2.32%
80 60 40 20 0
Ctrl
pW-TRE DDX5
OSKM
G Cell number (×10,000)
F
E
pW-TRE DDX5
MEFs
MEFs
**
100
**
3
250 200
OSKM+shCtrl OSKM+shDdx5
150 100 50 0
D0 D2 D4 D6 D8 D10
Cell number (×10,000)
3
***
Relative expression level
4
0
D
Ddx5 mRNA
Ddx5 mRNA Relative expression level
Relative expression level
5
C
Oct4-GFP colony number
B
A
250 200
OSKM OSKM+DDX5
150 100 50 0
D0 D2 D4 D6 D8 D10
Figure S2 (Related to Figure 2) A
B
Target site 1
Exon 2
Exon 1
Ddx5
NM_007840.3
Cas 9
target site Ddx5+/+ Ddx5-/-
Chr11
Ddx5-/- #2
PAM region
GACC GAGACCGCGGCCGGGATCGAGGGTGAGTGT CTGG CTCTGGCGCCGGCCCTAGCT CCCACTCACA GAGACCGCGGCCGGGATCGA
5‘
target site Ddx5+/+ Ddx5-/-
3’
Target site 2
Exon 1
Ddx5
Exon 2
NM_007840.3
Ddx5-/- #3 target site Ddx5+/+ Ddx5-/-
Chr11
Cas 9
PAM region
Ddx5-/- #4
CTCTGGAAAGAAGTTTGGAAATCCTGGGGAGAAA GAGACCTTTCTTCAAACCTTTAGGACCCCTCTTT GGAAAGAAGTTTGGAAATCC
5‘ 3’ 5‘
target site Ddx5+/+ Ddx5-/-
3’
C
D
/-
# x5 - 1 /Dd #2 x5 /#3
Relative expression level
1.4
Dd
x5 Dd
Dd
x5 +
/+
mESCs
α-DDX5 α-β-Actin
F
Ddx5
Ddx5-/-
1.2 1 0.8 0.6 0.4 0.2 0
+/+
E
Ddx5+/+
Nanog
Oct4
Sox2
-/-
Ddx5-/- #2
150
0
Utf1
D0
Ddx5 #2
0 50K
G2
200
S G1
0
100K 150K 200K PI-A
50K
400
200
100
G2
G1
0 50K
100K 150K 200K PI-A
G1/S : 28.99 S : 39.54 G2/M : 25.18
G1/S : 26.33 S : 39.74 G2/M : 28.38
G
S
200 100
G2
100K 150K 200K PI-A
0
H
G1 50K
G1/S : 26.53 S : 40.31 G2/M : 26.4
Relatvie expression leve
4
OSKM+shDdx5#1 OSKM+shDdx5#2
3
**
** **
**
1
TW 1 T2 D 5 -/dx #1 5 -/D dx #2 5 -/ D dx -#3 5 -/#4
0
dx
D
D3
G2
G1/S : 29.81 S : 37.4 G2/M : 26.81
OSKM+shCtrl
2
S
100K 150K 200K PI-A
Ddx5 mRNA
log2(Fold Change)
W
D3
Ddx5 #3
Count
Count
Count
G1
D2
300
100
S
D1 -/-
300
100
Ddx5-/- #3
300
300
200
Ddx5-/- #1
-/-
Ddx5 #1
300
Ddx5+/+
450 Numbers of cells (10,000)
5‘ 3’
Count
Ddx5-/- #1
D6
D9
D12
Figure S3 ( Related to Figure 3) B MEFs
p #1 sh Ry bp #2
0.8
α-β-Actin
100
0.2
trl sh R
12 9 6 3 Ctrl
pMXs RYBP
500 400 300 200
2 0
** *** ***
Zeb2
Cdh1
Krt8
Epithelial genes
100
10
shRybp
200 150 100 50 0
D0 D2
D4 D6 D8 D10
Cell number (×10,000)
Cell number (×10,000)
250
shCtrl
200
50 0
Ctrl
pW-TRE RYBP
***
***
***
***
Zeb2
Cldn3
Krt8
Mesenchymal genes
L 250
100
1
K 300
150
MEFs OSKM+shCtrl OSKM+shRybp#1 OSKM+shRybp#2 Snai1
0.1
OSKM
200
Epithelial genes
Mesenchymal genes
J
pW-TRE RYBP
***
250
MEFs
Relative expression level
Relative expression level
0.01 0.001 0.0001
MEFs OSKM OSKM+RYBP Snai1
4
RYBP
I
***
6
Ctrl
H 10000 1000 100 10 1 0.1
8
0 Ctrl
OSKM
***
10
100
MEFs
G
Rybp mRNA
Oct4-GFP colony number
15
F
Secondary MEFs +Dox +Vc ***
Relative expression level
Oct4-GFP colony number
***
0
yb p
sh C
yb p
yb p
sh C
sh R
sh R
E
Rybp mRNA 18
0
#2
#1
0
50
#2
0.4
150
yb p
α-RYBP
Secondary MEFs +Dox +Vc *** ***
#1
0.6
D Relative expression level
200
sh Ct rl sh Ry b
1
Oct4-GFP colony number
1.2
C
sh R
Rybp mRNA ** **
trl
Relative expression level
A
OSKM-RYBP-iPSCs
OSKM OSKM OSKM+RYBP 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
X
150 100 50 0
D0 D2 D4 D6 D8 D10
Y
OSKM
B
OSKM Oct4-GFP colony number
60 40 20 0
Ctrl 4.57%
6 5 4 3 2 1 0
-1
-m
pri
-2
5b
5b
12 iR-
12 iR-
1E-05
***
1E-05 8E-06 6E-06 4E-06 2E-06 0E+00
rl
Ct
1 2 5# x5# d D sh
1.2
***
1.0
0.4 0.2 0.0
rl
t hC
s
1 0.8 0.6 0.4 0.2 0
C
ti-N
an
a
5b
12 9 6 3 0
NC
ti-
an
OSKM+anti-miR-125b
200 150 100 50 0
50 0
D0 D2 D4 D6 D8 D10
*** ***
***
60
**
40 20 0
***
300
endo-Sox2
O
200
100
0 D0 D2 D4 D6 D8 D10
100
endo-Oct4
Nanog
MEFs
Oct4-GFP colony number
Cell number (×10,000)
250
150
80
a
N OSKM+anti-NC
200
MEFs OSKM+anti-NC OSKM+anti-miR-125b
100
1
iR-
-m nti
MEFs
M
b 25
2
OSKM+miR-125b
250
# x5
Dd sh OSKM D6
L
***
15
12
Rmi
nti
Rybp mRNA
K
1
# x5
Dd
sh
Relative expression level
***
Relative expression level
Relative expression level
J
miR-125b
Ctrl DDX5 anti-NC anti-miR-125b
+ + -
2.34%
Oct4-GFP
OSKM+NC
0.6
MEFs
1.2
***
0.8
x Dd
sh
miR-29a
FSC
FSC
**
sh
-m
pri
1E-05
Ctrl
I
miR-125b
Cell number (× 10,000)
7
Relative expression level to U6
(×10-4)
0
GFP
H
miR-125b
25
Oct4-GFP
+ + -
+ +
+ +
Utf1
***
500 Oct4-GFP colony number
G
Ddx5-/-
Relative expression level to U6
Relative expression level to U6
Ddx5+/+
50
2.14%
1.34%
Oct4-GFP
GFP
F
75
E
miR-125b
Oct4-GFP
p=0.342
100
80
C -log2 (Relative expression)
D
**
100 Oct4-GFP colony number
log2 (Foldchange)
A
Figure S4 (Related to Figure 4)
400 300 200 100
0 anti-NC anti-miR-125b shCtrl shRybp
+ + -
+ + -
+ +
+ +
Figure S5 (Related to Figure 5) A
B OSKM D4
D8
Ddx5+/+ mESCs H2AK119ub1
D12
Ddx5-/- mESCs H2AK119ub1
sh C tr sh l D dx sh 5 C trl sh D dx sh 5 C trl sh D dx sh 5 C trl sh D dx 5
D2
α-H2AK119ub1 1
0.95
0.88
1.36
1.39
1591
1.56 1.46 2.06
5908
1335
α-H3
C
D Unique in Ddx5+/+ mESCs
Common in Ddx5+/+ & Ddx5-/- mESCs GO Biolog ica l Pr oce ss pat t ern specificat ion process regionalizat ion em bryonic organ m orphogenesis cell fat e com m it m ent ant erior/post erior pat t ern specificat ion m esoderm m orphogenesis m esoderm form at ion m esoderm developm ent
GO Biolog ica l Pr oce ss
-log10(Binom ial p value) 0 5 10 15 20 25 30 35 40 45 50 55 60
48.41 43.97 37.61 34.88 32.83 30.17
m esoderm developm ent m esoderm m orphogenesis cart ilage developm ent m esoderm form at ion odont ogenesis developm ent al m at urat ion m onocyt e aggregat ion form at ion of prim ary germ layer
63.43 60.33
E Unique in Ddx5-/- mESCs
GO Biolog ica l Pr oce ss
-log10(Binom ial p value) 0 1 2 3 4 5 6 7 8 9 10 11
cerebellar cort ex developm ent cerebellum developm ent m et encephalon developm ent response t o ret inoic acid cell fat e com m it m ent hindbrain developm ent cerebellar cort ex m orphogenesis t ongue m orphogenesis
9.91 9.79 9.53 8.81 7.53 7.42 7.40
11.73
-log10(Binom ial p value) 0
2
4
6
8
10
9.14 8.41 8.00 7.52 7.43 6.46 6.14
12 13.63
Figure S6 (Related to Figure 5) A
Jun Ddx5
Tril
10 kbp
Chr4: 95031534-95087422 +/+
210
H2AK119ub1
Ddx5
10 210
Ddx5-/- H2AK119ub1
10
Fragment near Tril TSS
*
IgG
0.08
0.04 0.02
*
0.06
Ddx5+/+
**
8 6 4 2 0
shCtrl
1
Bmp4
IgG shDdx5 RYBP shDdx5
0.4 0.2 shCtrl
0.04 D5
H2AK119ub1 Ctrl H2AK119ub1 RYBP
D5
*
0.12
10 5
D11
IgG shDdx5 RYBP shDdx5
0.04 0
D5
D11
OSKM
H2AK119ub1 Ctrl H2AK119ub1 RYBP
25
**
**
20 15
5
5 D11
OSKM
0
H2AK119ub1 Ctrl H2AK119ub1 RYBP
* *
15 10
D5
IgG Ctrl IgG RYBP
20
10
0
shDdx5
0.08
D11
25 % Input
*
OSKM
shCtrl
Klf15
IgG Ctrl IgG RYBP
*
D5
2
OSKM
20 % Input
*
Bmp4
15
4
IgG shCtrl RYBP shCtrl
% Input
0
Egr4
0
IgG shDdx5 RYBP shDdx5
0.04
D11
IgG Ctrl IgG RYBP
6
OSKM
0.08
OSKM
E
8
0
shDdx5
*
0.12 % Input
% Input
**
***
Rasd1
IgG shCtrl RYBP shCtrl
**
0.16
Ddx5-/-
10
0.6
Jun
0.08
Klf15
14
OSKM
Tril
0
**
12
OSKM
0.12
Ddx5+/+
mESCs
0.8
0
shDdx5
IgG shCtrl RYBP shCtrl
0.04
0
Ddx5-/-
% Input
Relative expression level
10
Egr4
0.06
mESCs
Relative expression level
C
*
0.02
0
Ddx5-/-
RYBP
0.08
0.04
mESCs
D
IgG
Relative expression level
Ddx5+/+
Rasd1
Fragment near Rasd1 TSS
0.02
0
1
RYBP
% Input
0.06
% Input
% Input
RYBP
1 23
Med9
Tril
IgG
23
H2AK119ub1
Ddx5-/- H2AK119ub1
10
Fragment near Jun TSS
0.08
Ddx5
10 210
Ddx5-/- H2AK119ub1
1 kbp
Chr11: 59943181-59984944 +/+
210
H2AK119ub1
Jun
B
Rasd1
10 kbp
Chr6: 53795466-53840830 +/+
D11
D5
OSKM
Figure S7(Related to Figure 7)
0.2 Oct4
Nanog
Esrrb
Utf1
+ + -
+ +
+ + -
1
0.1 Flag shLuc shKdm2b RYBP
+ +
/-
DD
X5 -
DD
*
DD
*
*
1.6
X5 +
/+
Kdm2b
2
+ + -
+ + -
1#
E
1
1.15
1.31
1.34
α-KDM2B
1.2 0.8
α-DDX5
0.4
3#
/-
2#
/-
X5 DD
1#
X5 -
/-
DD
X5 -
DD
X5 +
/+
0 DD
Relatvie expression level
D
0.1 Flag shLuc shRybp KDM2B
10
DD
0
1
Kdm2b
α-β-actin
3#
0.4
10
Rybp
/-
0.6
100
Kdm2b
2#
1 0.8
Rybp
X5 -
100
1.2
OSKM
/-
Rybp mESCs Rybp-/- mESCs Relative expression level
Relative expression level
1.4
C
OSKM
X5 -
B +/+
Relative expression level
A
+ +
+ +
SUPPLEMENTAL LEGENDS Figure S1. Related to Figure 1. DDX5 Perturbs Reprogramming. (A) qRT-PCR analysis for Ddx5 mRNA expression at different time points of MEFs reprogrammed with OSKM. (B) qRT-PCR analysis of Ddx5 expression after overexpression with pMXs-DDX5 vector in MEFs. (C) qRT-PCR analysis of Ddx5 expression after overexpression with pW-TRE-DDX5 in MEFs. (D) Number of GFP+ colonies of MEFs transduced with OSKM and either empty plasmid or pW-TRE-DDX5 at day 10. (E) GFP+ cells analyzed by FACS in reprogrammed cells transfected with OSKM and either empty plasmid or pW-TRE-DDX5 at day 10. (F) Cell proliferation at different time points during OSKM reprogramming with control shRNA or Ddx5 shRNA. (G) Cell proliferation at different time points during OSKM reprogramming with either empty plasmid or Flag-DDX5. The data in (A-D) and (F-G) are reported as mean values ± SD with the indicated significance by using Student’s t-test analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data in (A-C) and (F-G) are plotted from 3 independent experiments each with 3 technical replicates. Data in (D) is plotted from 4 independent experiments each with 3 technical replicates. Figure S2. Related to Figure 2. Strategies of Generating Ddx5-/- mES Cell Lines and the Effects of DDX5 Loss-of-Function on Gene Expression, Cell Proliferation, Cell Cycle. (A) A schematic illustration of the Ddx5 knockout strategy using CRISPR/Cas9 in mESCs. (B) DNA sequencing diagram of Ddx5 proximal to target site in Ddx5+/+ and Ddx5-/- mESCs. (C) Western blot to examine Ddx5 knockout efficiency of three different Ddx5-/- mESCs. β-Actin was used as the loading control. (D) qRT-PCR analysis for the expression of pluripotent genes in Ddx5 +/+ and Ddx5-/- mESCs. (E) Cell proliferation of wild type and three different Ddx5 -/- mES cell lines at different time points. (F) Cell cycle assay of wild type and Ddx5-/- mESCs. Three different Ddx5-/- mES cell lines were used. (G) Heatmap of the expression of epigenetic-associated genes and other selected genes in wild-type and Ddx5-/- mESCs. Log2 relative gene expression is visualized as shades of red (higher than Ddx5 +/+ mESCs) and shades of blue (lower than Ddx5 +/+ mESCs) in Ddx5-/- mESCs. Two wild-type and four Ddx5-/- mESC lines were used. (H) qRT-PCR analysis for Ddx5 knockdown efficiency in MEFs transduced with shRNA for Ddx5 during reprogramming. The data in (D), (E) and (H) are reported as mean values ± SD with the indicated significance by using Student’s t-test analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data in (D), (E) and (H) are plotted from 3 independent experiments each with 3 technical replicates.
Figure S3. Related to Figure 3. Loss of RYBP Inhibits Somatic Cell Reprogramming. (A) qRT-PCR analysis for Rybp knockdown efficiency of MEFs reprogrammed with OSKM plus control shRNA or Rybp shRNA. (B) Western blot for RYBP knockdown efficiency using cell lysates from MEFs reprogrammed with OSKM plus control shRNA or Rybp shRNA. β-Actin was used as the loading control. (C) Number of GFP+ colonies in doxycycline-inducible secondary MEFs transduced with control shRNA or two shRNAs targeting Rybp at day 12. (D) qRT-PCR analysis of Rybp expression after pMXs-RYBP overexpression in MEFs. (E) Number of GFP+ colonies in doxycycline-inducible secondary MEFs transduced with empty vector or Flag-RYBP at day 12. (F) qRT-PCR analysis of Rybp expression after pW-TRE-RYBP over-expression in MEFs. (G) Number of GFP+ colonies of MEFs transduced with OSKM and either empty plasmid or pW-TRE-RYBP at day 10. (H) qRT-PCR analysis for the MET genes using RNA lysates from MEFs reprogrammed with OSKM and empty vector or RYBP at day 5. Untransduced MEFs were used for normalization. (I) qRT-PCR analysis for the MET genes using RNA lysates from MEFs reprogrammed with OSKM and shRNA control or 2 shRNAs for Rybp at day 5. Untransduced MEFs were used for normalization. (J) Cell proliferation at different time points during OSKM reprogramming with control shRNA or Rybp shRNA. (K) Cell proliferation at different time points during OSKM reprogramming with empty vector or RYBP. (L) Karyotype of a selected iPSC colony generated with OSKM and RYBP. The data in (A) and (C-K) are reported as mean values ± SD with the indicated significance by using Student’s t-test analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data in (A), (D), (F) and (H-K) are plotted from 3 independent experiments each with 3 technical replicates. Data in (C), (E) and (G) are plotted from 4 independent experiments each with 3 technical replicates. Figure S4. Related to Figure 4. miR-125b Is A Barrier for Reprogramming. (A) A MA plot with dots marked red and blue colors indicating miRNAs significantly regulated (p